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Abbreviation list 
AH absolute humidity 
BPD bronchopulmonary dysplasia 
CO2 carbon dioxide 
CPAP continuous positive airway pressure 
eMV endotracheal mechanical ventilation 
GA gestational age 
HFNC high-flow nasal cannula 
HFOV high-frequency oscillatory ventilation 
I:E ratio inspiratory-to-expiratory ratio 
IVH intraventricular hemorrhage 
LISA less invasive surfactant administration 
MIST minimally invasive surfactant therapy 
nBiPAP nasal bilevel positive airway pressure 
nCPAP nasal continuous positive airway pressure 
nHFOV nasal high-frequency oscillatory ventilation 
NICU neonatal intensive care unit 
nIPPV  nasal intermittent positive pressure ventilation 
nsBiPAP nasal synchronized bilevel positive airway pressure 
nsIPPV nasal synchronized intermittent positive pressure ventilation 
RCT randomized controlled trial 
RDS respiratory distress syndrome 
RR respiratory rate 
SpO2 peripheral oxygen saturation 
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1. Introduction
1.1 Modes of non-invasive respiratory support in neonates 
Modern neonatal intensive care offers a broad range of methods to support infants with 
respiratory failure. Although severely affected patients still require endotracheal 
mechanical ventilation (eMV) or even adjunctive therapies, such as inhaled nitric oxide 
or extracorporeal membrane oxygenation,1 most neonates can nowadays be stabilized 
by non-invasive modes of respiratory support. Current techniques are listed in Tab. 1, 
and can be grouped into methods that apply a constant airway pressure and methods 
that apply a variable airway pressure.2 In addition, low-flow supplemental oxygen is 
used as a method to provide oxygen without significant pressure transmission to the 
airways. 
 Tab. 1 Current techniques of non-invasive respiratory support. 
Type of pressure 
applied 





Low-flow supplemental oxygen Established method    




High-flow nasal cannula (HFNC) Recently established method 
Nasal continuous positive airway 
pressure (nCPAP) 
Standard of care 
Variable airway 
pressure 
Nasal bilevel positive airway 
pressure (nBiPAP) 
Established method 
Nasal intermittent positive pressure 
ventilation (nIPPV) 
Established method 
Nasal synchronized bilevel positive 
airway pressure (nsBiPAP) 
Prevalence limited, 
clinical studies 
Nasal synchronized intermittent 




Nasal high-frequency oscillatory 
ventilation (nHFOV) 
Prevalence limited,     
case series, pilot studies 
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Clinical use of the diverse respiratory support modes may vary considerably from one 
neonatal intensive care unit (NICU) to another, and there is a multitude of different 
equipment available. 
Apart from various devices that provide the actual mode of non-invasive respiratory 
support, different tubing systems and heated humidifiers are applied.3 Moreover, there 
is a multitude of interfaces, including single and binasal prongs of different lengths and 
diameters, nasopharyngeal tubes, nasal masks, nasal cannulae, and helmets.2,4-7 
Clinical studies that attempted to prove the superiority of specific devices or interfaces 
mostly yielded inconsistent results and were focused on short-term outcomes. There 
is a consensus, though, that short binasal prongs have a lower resistance and are 
more effective at preventing reintubation than single nasal or nasopharyngeal 
prongs.4,8,9 
Surveys that investigated the prevalence of non-invasive respiratory support modes 
showed that nasal continuous positive airway pressure (nCPAP) is the current 
standard of care for the treatment of neonatal respiratory disorders. In comparison, 
nasal bilevel positive airway pressure (nBiPAP) and nasal intermittent positive 
pressure ventilation (nIPPV) are less frequently applied.10-12 Moreover, dedicated 
surveys reflect the rapid increase in the clinical use of heated humidified high-flow 
nasal cannula (HFNC).13,14 In addition, nasal synchronized bilevel positive airway 
pressure (nsBiPAP) and nasal synchronized intermittent positive pressure ventilation 
(nsIPPV) are being investigated in clinical studies.15,16 Reports about nasal high-
frequency oscillatory ventilation (nHFOV) mostly relate to pilot trials and case 
series.17,18 
A recent clinical report by the American Academy of Pediatrics recognized that the 
newer modalities such as nBiPAP, nsBiPAP, nIPPV, nsIPPV and HFNC may offer 
some advantages over nCPAP, but warned that efficacy and safety data are still 
limited.19 
5
1.2 Mechanisms of action 
All in all, the aforementioned methods of non-invasive respiratory support rely on four 
basic mechanisms of action: 
1. Pressure transmission to airways and lungs (not during low-flow oxygen)
2. Airflow that enters the airways at the level of the interface
3. Oxygen supplementation (possible with all methods)
4. Pressure oscillations
The major feature of continuous positive airway pressure (CPAP) is the application of 
continuous distending pressure. This pressure splints the upper airways,20 decreases 
supraglottic and total pulmonary resistance,21,22 increases functional residual 
capacity,23 and improves the recruitment of the lungs.24 It is understood that the 
increased end-expiratory lung volume stabilizes the infant’s compliant chest wall and 
improves thoracoabdominal synchronization.25,26 The overall effect is a reduced work 
of breathing.27 Moreover, the distending pressure reduces obstructive apneas28 and 
may preserve stability of oxygenation during central apneas.29  
There are different devices available to generate the CPAP, which either use 
continuous flow or variable flow technology. Continuous flow devices deliver a constant 
background flow to the inspiratory limb of the breathing circuit, while the CPAP is 
generated by an adjustable resistance to gas flow at the end of the expiratory limb. 
This adjustable resistance may be the expiratory valve of a neonatal ventilator during 
ventilator-derived CPAP or an underwater seal during bubble CPAP.2 By contrast, 
variable flow devices generate the CPAP pressure close to the nasal orifices via a jet 
stream passing through an opening in the nosepiece.30,31 Some of these devices use 
the Coandă effect to attach the jet stream to different surfaces during inspiration and 
expiration. This “fluidic flip” technology reduces expiratory resistance and may achieve 
more stable pressure at the airway with additional reduction in work of breathing.30,32--35 
During bubble CPAP, the bubbles create pressure oscillations that are transmitted 
back to the airway opening. This noisy pressure waveform is superimposed on the 
pressure fluctuations of spontaneous breathing, and may promote airway opening 
events and lung volume recruitment as a result of stochastic resonance.36 Moreover, 
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the pressure oscillations of bubble CPAP may contribute to effective ventilation by 
unconventional mechanisms of gas exchange, such as facilitated diffusion.37,38 
Presumably, the flow that enters the airways during CPAP is also important, as it 
facilitates expiration by a flow-dependent washout effect of carbon dioxide (CO2) from 
the pharyngeal dead space.39 
During HFNC, similar flow-related washout effects exist and are probably the most 
important mechanism of action.40 Because the HFNC does not have a snug fit in the 
nares, additional washout effects may occur at this level.39 By contrast, transmission 
of distending pressure is probably less important during HFNC, as bench studies 
showed that pressures obtained are highly variable and depend on a multitude of 
factors, such as the flow rate, cannula size and nares diameter.41,42 Even with less 
distending pressure, however, HFNC may reduce resistive work of breathing in the 
upper airways during inspiration by provision of gas flows that match or exceed the 
patient’s peak inspiratory flow.43 Notably, clinical studies found that the overall work of 
breathing may be similar during nCPAP and HFNC.40,44 
As low-flow oxygen lacks the specific action mechanisms of CPAP and HFNC 
described above, it is nowadays hardly used in the acute phase of neonatal respiratory 
disease, but matters if the weaning phase is prolonged, particularly if long-term oxygen 
treatment is required in preterm infants with severe bronchopulmonary dysplasia 
(BPD), Tab. 1.45,46 
At the other end of the spectrum, non-invasive respiratory support modes such as 
nBiPAP, nIPPV, nsBiPAP, nsIPPV and nHFOV attempt to provide “more potent” 
respiratory support. These techniques combine the provision of continuous distending 
pressure with variable elevations of the airway pressure to recruit the lungs more 
efficiently and facilitate CO2 exhalation. 
While BiPAP primarily aims at more effective lung volume recruitment by application 
of a cyclic shift between a lower and slightly elevated positive airway pressure 
(generally no more than 11 cm H2O), nIPPV provides higher inspiratory pressures and 
shorter inspiratory times to expand the lungs, similar to eMV.15 Unfortunately, the non-
invasive ventilation breaths are rarely transmitted to the chest if they are not 
synchronized with the infant’s respiration.47 Therefore, triggered methods such as 
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nsBiPAP and nsIPPV seek to synchronize the non-invasive ventilator breaths with 
patient breathing. Synchronization may be achieved by a flow trigger48, a pneumatic 
capsule taped to the abdomen in the subxiphoid area,49 neurally adjusted ventilatory 
assist,16,50 or transcutaneous electromyography of the diaphragm.51 
NHFOV is an innovative mode of non-invasive respiratory support that aims to combine 
the positive effects of CPAP with the additional benefits of high-frequency pressure 
oscillations superimposed on the patient’s tidal breathing. The method has a major 
advantage in that it does not require patient-ventilator synchronization.52 
Hypothetically, the oscillatory pressure waveform of nHFOV induces unconventional 
mechanisms of gas exchange similar to those identified in invasive high-frequency 
oscillatory ventilation (HFOV).38 The impact of the pressure oscillations on CO2 
clearance is considered greater during nHFOV than bubble CPAP, as nHFOV 
oscillations are more powerful and have an active expiratory phase.17 In line with these 
assumptions, bench studies showed that nHFOV enhances CO2 elimination.53,54 
Clinical observational studies and a small crossover trial were able to confirm this effect 
in the clinical setting.55-57 
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1.3 Clinical efficacy 
Non-invasive respiratory support may be used in the acute phase of neonatal 
respiratory disorders, the weaning phase, or both. Appropriate choice of non-invasive 
treatment depends on several factors, such as the nature and severity of the disease, 
the maturity and age of the patient, the actual clinical setting, and the effective 
combination with potent pharmacological agents. 
To establish the efficacy of these interventions, clinical studies investigated specific 
non-invasive treatment strategies in various respiratory conditions. In neonates, 
probably the largest amount of clinical research was devoted to the investigation of 
non-invasive respiratory support in the treatment of premature infants with respiratory 
distress syndrome (RDS). These efforts were mainly undertaken to reduce major 
complications of RDS, such as mortality and BPD. 
BPD has long been recognized as a pulmonary sequela of eMV and oxygen 
supplementation in surfactant-deficient lungs.58,59 Subsequently, however, it was 
acknowledged that BPD is a multifactorial disease of very preterm infants that can also 
develop without prolonged exposure to oxygen or eMV. This so-called “new BPD” is 
related to a maturational arrest of the evolving lung. It initially manifests as mild 
respiratory distress, but leads to increased oxygen requirements and disturbed lung 
development thereafter.59,60 Today, BPD is still a common complication of 
prematurity,61 and is associated with long-term impairment of lung function, increased 
risk of asthma, worse neurodevelopmental outcomes, impaired school achievement, 
and reduced health-related quality of life.62-64  
In 1987, a cohort study by Avery et al. revealed that the early use of bubble CPAP 
instead of eMV was associated with a considerably lower incidence of BPD.65 At the 
time, however, prospective trials did not investigate this finding further. Quite the 
opposite, clinical research in the 1990s focused on strategies of early intubation and 
endotracheal surfactant administration, followed by brief eMV and extubation to 
nCPAP, as this approach appeared to be associated with the lowest incidence of air 
leak syndromes and BPD.66 
After 2000, there was renewed interest in using nCPAP as a primary mode of 
respiratory support in very premature infants. This had several reasons: First, registry 
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data revealed that the incidence of BPD remained high in very low birth weight infants 
≤28 weeks’ gestational age (GA), in spite of widespread use of antenatal steroids and 
early surfactant administration.61 Second, animal studies showed that complete 
avoidance of eMV by nCPAP treatment reduced indicators of acute pulmonary injury 
in alveolar washes. This suggested that avoiding eMV altogether had the potential to 
prevent activating the inflammatory cascade in the lung that leads to BPD.67 Third, 
several multi-center randomized controlled trials (RCTs) were recruiting patients that 
compared nCPAP as a primary mode of respiratory support versus prophylactic or 
early selective surfactant treatment.68-70 In addition, less invasive ways of surfactant 
administration during nCPAP were explored71,72 and tested in RCTs.73,74 When the 
present thesis was devised in 2012, data from the aforementioned RCTs were 
available or upcoming, and some showed trends towards a reduction in BPD. Up until 
then, however, these results had not been evaluated systematically in a meta-analysis. 
Apart from nCPAP, other non-invasive modes of respiratory support are being used in 
neonates, although there is considerably less evidence from clinical trials to document 
their efficacy. 
HFNC is nowadays recognized as an alternative to nCPAP in many clinical settings. 
The main advantage of HFNC appears to be its ease of use. Moreover, it allows better 
access to the infant’s face, thus facilitating feeding and bonding with parents.14 A 
Cochrane Review in preterm infants analyzed RCTs that compared HFNC with nCPAP 
after birth (four studies, 439 patients) and for post-extubation support (six studies, 934 
patients). The analyses found no difference in the incidence of death, BPD or treatment 
failure.75 A recent multi-center RCT, however, compared HFNC with nCPAP after birth 
in 546 infants ≥28 weeks’ GA and showed that treatment failure occurred more 
frequently in the HFNC group (26% versus 13%).76 Moreover, concerns have been 
raised that HFNC may prolong the weaning phase and exposure to supplemental 
oxygen.77,78 Further knowledge gaps include the lack of efficacy data about HFNC use 
in premature infants <28 weeks’ GA and its impact on long-term outcomes. 
Non-invasive respiratory support modes that apply a variable airway pressure aim to 
be more efficient at avoiding eMV than nCPAP, and thereby seek for a reduction of 
BPD rates. To date, however, a beneficial effect of these modalities on the incidence 
of BPD could not be proven. A recently updated Cochrane review compared RCTs that 
applied various forms of nIPPV, nsIPPV and nBiPAP versus nCPAP in extubated 
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preterm infants (10 studies, 1431 patients). In the intervention group, there was a 
decreased risk of respiratory failure and less need for reintubation, but no difference in 
death or BPD. Interestingly, a subgroup analysis of nsIPPV versus nCPAP was 
associated with a reduction in BPD (three studies, 181 patients).79 Therefore, future 
RCTs should be devised to investigate nsIPPV as an alternative to nCPAP in preterm 
infants with RDS, and should consider the use of advanced triggering equipment such 
as NAVA.50 Admittedly, the use of NAVA technology may be intricate in VLBW infants. 
For these patients, nHFOV might be a suitable alternative to augment gas exchange, 
as patient-ventilator synchronization is not needed during nHFOV.52 As previously 
mentioned, however, available cohort studies and pilot trials of nHFOV focused on 
short-term outcomes such as pCO2 and were not powered to investigate the effects of 
nHFOV on long term treatment efficacy.17,18 
11
1.4 Adverse effects 
There are a number of specific adverse effects associated with the use of non-invasive 
respiratory support in newborn infants.  
At the level of the interface, local adverse effects are a major concern. In particular, the 
prolonged use of binasal prongs may lead to progressive flaring of the nostrils, circular 
distortion of nares, and flattening of alar ridges.80 Studies of nasal prong CPAP 
reported an incidence of nasal injuries between 20 and 60%.80-82 Redness, crusting 
and excoriation typically occurs at the nasal septum.82 In severe cases, columella 
necrosis has been reported and may require plastic reconstruction later in childhood.83 
Meticulous nursing care, including appropriate choice of nasal prong size and proper 
fixation, are paramount to reducing the aforementioned complications.84 The use of 
nasal masks has recently been reported to reduce the incidence of severe nasal 
trauma during CPAP therapy,85 but nasal masks themselves may cause lesions at the 
junction between the nasal septum and the philtrum.82 
Pressure transmission to the airways and lungs is associated with increased risks of 
pneumothorax and other air leaks.86 In preterm infants, two multi-center RCTs of 
nCPAP reported higher pneumothorax rates of 9% in the CPAP-treated groups, in 
comparison with only 3% in the groups that received earlier intubation and 
surfactant.68,87 However, similar multi-center RCTs did not replicate these findings,69,70 
and current guidelines recommend nCPAP with early rescue surfactant administration 
as a safe alternative to intubation and prophylactic surfactant in the postnatal treatment 
of premature infants with RDS.9,88 A more recent RCT even reported lower 
pneumothorax rates of 4.8% and increased survival without major complications if 
surfactant was administered via a thin catheter during nCPAP, while the pneumothorax 
rate was 12.6% in the group that was intubated for surfactant administration.89 
Benign gaseous distention of the bowel has been reported in preterm infants treated 
with nCPAP, and may lead to unnecessary contrast studies and surgery.90 This clinical 
presentation has been denoted as “benign CPAP belly syndrome,” as it is not 
associated with abdominal complications. Although there are some concerns that the 
gaseous distention of the bowel may prolong the duration to achieve full enteral 
feeds,91 an ultrasound study in very low birthweight infants even reported faster gastric 
emptying during nCPAP therapy.92 
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Noise exposure may be substantial during certain modes of respiratory support. Bench 
studies showed particularly high noise intensities during variable flow CPAP,93 helmet 
CPAP,7 and HFNC.94 Clinical studies in neonates confirmed that noise levels during 
variable flow CPAP, bubble CPAP and HFNC often exceeded currently recommended 
limits, and there are concerns that this may negatively impact preterm infants’ 
hearing.95-97
Supplementation of oxygen is often required during non-invasive respiratory support 
and involves a broad range of risks for neonates. Preterm infants are especially 
susceptible to oxidative stress,98 and hyperoxia is a recognized factor in the 
pathogenesis of developmental diseases of prematurity, such as BPD58,59,99,100 and 
retinopathy of prematurity.101,102 However, the early use of non-invasive respiratory 
support instead of eMV aims to reduce the cumulative duration of any respiratory 
support and may also reduce aggregate exposure to supplemental oxygen. 
Overall, most data about adverse effects of non-invasive respiratory support relate to 
nCPAP trials, and there is much less data about other respiratory support modes. In 
the case of HFNC, specific concerns have been raised about the occurrence of air 
leaks due to the unpredictable pressure transmission.103-105 However, bench studies 
and clinical data indicate that excessive pressure transmission can be avoided by 
appropriate choice of nasal cannula prong size and the use of a pressure relief valve 
in the circuit.41,106 Encouragingly, a recent meta-analysis showed that the rate of air 
leak during HFNC was comparable to that with nCPAP.107 With regard to nIPPV, early 
reports raised concerns about the occurrence of intestinal perforation,108 but an 
updated Cochrane review did not substantiate these concerns.79 For nsIPPV, 
nsBiPAP, and nHFOV, there is hardly any published information about adverse effects. 
Finally, it is important to note that the use of nCPAP and other non-invasive respiratory 
support modes is only safe if the patient’s respiratory effort is sufficient to ensure 
adequate ventilation. Hypercapnic respiratory failure may evolve unnoticed in preterm 
infants and has been associated with an increased incidence of severe intraventricular 
hemorrhage (IVH),109 especially during the first days of life.110 Therefore, the aggregate 
data from RCTs about non-invasive respiratory support should be carefully and 
systematically analyzed for the incidence of side effects to verify the safety of 
innovative treatment approaches. 
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1.5 Significance of leaks 
Leaks are a major issue during non-invasive respiratory support of neonates, as they 
have been shown to affect the efficacy of treatment. Moreover, they may be associated 
with specific side effects that add to those already mentioned. 
Theoretically, leaks can occur at any location between the ventilatory device and the 
lungs. This may be due to technical problems, such as an improperly connected tubing 
system or a leakage at the interface’s level, such as a nares-prong leak. In this sense, 
the term “leak” refers to a respiratory support system that is not airtight.111  
Depending on the interface, leaks may be frequent during non-invasive respiratory 
support. In neonates, the common use of nasal interfaces allows the continuous loss 
of air through an open mouth, often denoted as “mouth leak.” Moreover, the fit of nasal 
masks or nasal prongs is often not airtight, nasopharyngeal tube interfaces implicate 
leaks through the contralateral nostril, and nasal cannulae involve an intentional leak 
at the nares’ level.2 Surprisingly, quantitative information about the incidence and 
magnitude of such leaks in infants is scarce.112,113 In a previous neonatal crossover 
study, we measured the leak during nasopharyngeal CPAP, with and without nostril 
occlusion. Spontaneous mouth opening was observed in more than 75% of all 
measurements. Leaks were almost invariably present and mostly exceeded the given 
measuring range of >90%, corresponding to leak flows of >1.4 l·min-1.114 
Hypothetically, such leaks impair successful treatment with non-invasive respiratory 
support in various ways: 
First, leaks reduce the efficacy of the pressure transmission to the airways by 
introducing a discontinuity between the ventilatory device and the lungs.111 A neonatal 
bench model of nCPAP demonstrated considerable pressure drops from the prongs to 
the test lung when nares-prong leaks were simulated.115 In line with these results, a 
clinical study in 11 preterm infants on binasal bubble CPAP showed an increase in 
pharyngeal pressure when the mouth was actively closed.116 The actual effects of leaks 
on oxygenation and breathing patterns, however, have never been investigated in 
infants. 
Second, leaks may impede triggering during nsBiPAP or nsIPPV if airway pressure or 
flow-triggering systems are used for synchronization. However, specially designed flow 
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triggers exist that are less sensitive to leaks,48 and other innovative triggering methods 
such as NAVA or diaphragmatic electromyography may circumvent this problem 
altogether.16,51 
Third, continuous bedside monitoring of tidal breathing parameters would be desirable 
during non-invasive respiratory support to guide treatment, but leaks were shown to 
interfere with such measurements.113,114,117 
The presence of leaks may also have positive effects on gas exchange, as leaks 
facilitate CO2 exhalation. During HFNC, the intentional leak around the nasal cannula 
and the high flow rate may prevent expired gas from reentering the nasal prongs, thus 
eliminating apparatus dead space. In line with this hypothesis, a recent bench study 
reported considerably lower CO2 washout times during HFNC than during nCPAP, 
even when a mouth-closed condition was simulated.39 In the same study, the quickest 
CO2 washout occurred with the mouth-open condition, no matter whether HFNC or 
nCPAP was applied. This observation can be explained by a unidirectional gas flow in 
through the nose and out through the mouth.118,119 Hypothetically, such a continuous 
leak flow effectively reduces ventilatory dead space by CO2 washout from the naso- 
and oropharynx and supersedes CO2 exhalation via the nasal airway route.39,53 
Unfortunately, the unidirectional leak flow through the mouth also involves a range of 
undesired effects. These effects were well documented in adults receiving CPAP 
treatment, and include sensations of oral and nasal dryness, increases in nasal 
mucosal blood flux and resistance, and congestion of nasal airways.118-120 It should be 
noted that sedated patients and small children are unable to declare such symptoms, 
and it is likely that similar adverse effects exist in infants. The impact of leaks on upper 
airway dryness, however, has never been investigated systematically in infants on non-
invasive respiratory support. 
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1.6 Significance of heated humidification 
Adequate heating and humidification of breathing gas are crucial to preventing adverse 
effects associated with heat loss and airway desiccation during non-invasive 
respiratory support.121 In preterm infants, it has also been suggested that the provision 
of warmed and humidified gas increases HFNC’s efficacy by minimizing the metabolic 
work of breathing, and improving respiratory conductance and pulmonary 
compliance.6,43,122 
Under normal circumstances, the nose and upper respiratory tract heat and humidify 
the inspired air in order to achieve constant gas conditions within the lungs.123 Dery et 
al. investigated the resulting temperature and humidity gradients along the respiratory 
tract in adults breathing room air, and found that the gas reached 37°C and 100% 
relative humidity five cm below the carina.124 The position of this “isothermic saturation 
boundary,” however, depends on the heat and moisture content of the inspired air, and 
moves further downward during oral breathing or with increased minute 
ventilation.125127 
During eMV, bypassing the upper airways places a greater burden of gas conditioning 
on the lower airways. Insufficient heating and humidification of the delivered breathing 
gas is associated with histological damage and functional impairment of the airway 
mucosa, including the ciliated epithelium in the tracheobronchial tree.123 This leads to 
increased mucous viscosity, depressed cilicary function, and impaired mucociliary 
clearance of secretions, which increases the risk of airway obstruction and respiratory 
infection. Moreover, the loss of body water and heat may have important clinical 
implications in infants, who have a higher minute ventilation-to-body surface area 
ratio.128 
During non-invasive respiratory support, inspired gas passes through the upper 
airways where it is conditioned, but the high flow rates applied may overwhelm the 
usual airway humidification mechanisms, especially in the presence of leaks.121 As 
previously mentioned, the mouth leak is a well-recognized problem in adult patients on 
CPAP, as the unidirectional leak flow through the mouth causes severe desiccation of 
the naso- and oropharynx, increased nasal resistance, and increased nasal 
congestion.119,120 Interestingly, these adverse effects could be attenuated by heated 
humidification of the breathing gas.119,129 In neonates, only a few studies genuinely 
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investigated gas conditioning during non-invasive respiratory support. A long time ago, 
a small cohort study in premature infants reported that crusting and clogging of 
nasopharyngeal CPAP tubes could be prevented by heated humidification.130 A 
randomized crossover trial of 12 preterm infants on nCPAP compared two temperature 
settings of the heated humidifier, but did not detect consistent effects on vital 
parameters.131 Recently, a neonatal manikin study systematically assessed the effects 
of HFNC, low-flow oxygen and various modalities of nCPAP on oropharyngeal gas 
conditions during heated humidification. The tested devices all achieved 
oropharyngeal temperature >33°C and relative humidity >80%. This study, however, 
did not simulate the effects of patient breathing and did not investigate the impact of 
mouth leaks.3 
In spite of the limited published evidence about gas conditioning in neonates, heated 
humidifiers are nowadays a key component of the ventilatory circuit during non-
invasive respiratory support. Specifically, there is a consensus that heated 
humidification is a prerequisite for the use of HFNC, which applies the flow of 2-8 l·min-1 
to the neonatal nose, which would otherwise cause adverse effects.6,43 The devices 
themselves have technologically evolved over the years.132 In neonatal intensive care, 
servo controlled pass-over humidifiers are frequently used. These devices apply 
“single point temperature control” algorithms to target a constant temperature at the 
chamber outlet.133 Unfortunately, these devices are strongly influenced by 
environmental conditions and ventilatory settings.134 Therefore, the efficacy of heated 
humidification should be investigated actively whenever novel modes of respiratory 
support are developed in preterm infants. Notably, a neonatal bench study of invasive 
HFOV showed larger water losses for low HFOV frequencies and high amplitudes,135 
but gas conditioning has never been explored during nHFOV. 
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1.7 Aims and objectives 
In summary, available evidence about the efficacy and side effects of non-invasive 
respiratory support justifies the frequent use of these treatments in the NICU. However, 
clinical studies in infants mostly related to nCPAP, and many open questions remain. 
Non-invasive strategies that avoid eMV in the primary treatment of RDS are evolving, 
but the significance of these approaches needs to be assessed, especially with regard 
to the prevention of BPD and other complications of prematurity. Further knowledge 
gaps relate to the impact of leaks on the efficacy of non-invasive respiratory support. 
Moreover, little is known in neonates about leak-related side effects and the impact of 
heated humidification. Finally, much more research is needed on innovative modes of 
non-invasive respiratory support, such as nHFOV. 
The present habilitation thesis aimed to address these issues in order to extend the 
knowledge about the efficacy and adverse effects of non-invasive respiratory support 
in neonates. Specifically, the following research objectives were pursued: 
1. To investigate the impact of non-invasive respiratory support strategies on BPD and
IVH in a meta-analysis of RCTs, considering published and previously unpublished 
stratified data for infants <30 weeks’ GA. 
2. To analyze the effects of nose and mouth leaks on oxygenation and respiratory rate
(RR) during neonatal CPAP, using data from a clinical crossover study. 
3. To obtain information about the prevalence, clinical practice and side effects of
nHFOV in an international survey. 
4. To develop a neonatal bench model suitable to investigate the impact of leaks and
heated humidification on oropharyngeal temperature and humidity during nCPAP. 
5. To investigate the effects of nHFOV on oropharyngeal gas conditions in the
previously designed bench model. 
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2. Original research
2.1 Impact of strategies to avoid endotracheal mechanical ventilation 
on the incidence of bronchopulmonary dysplasia in preterm infants 
<30 weeks’ gestational age 
Fischer HS, Bührer C. Avoiding endotracheal ventilation to prevent bronchopulmonary 
dysplasia: a meta-analysis. Pediatrics. 2013;132(5):e1351-1360 
To assess the clinical benefits of avoiding eMV in premature infants at high risk of BPD, 
we performed a meta-analysis of RCTs in preterm infants <30 weeks’ GA. The primary 
outcome was the incidence of death or BPD, defined as oxygen treatment at 36 weeks’ 
GA.59 As preterm infants are particularly vulnerable to IVH during the first days of 
life,109,110 severe IVH (Papile grade three or four) was investigated as a secondary 
outcome.136 RCTs were eligible for meta-analysis if they compared a strategy that 
aimed at avoidance of eMV with a control group in which eMV was performed at an 
earlier stage. Data search, extraction and analysis followed the standard methodology 
of the Cochrane Neonatal Review Group.137 After completing the literature search, we 
requested previously unpublished stratified data from the corresponding authors of two 
RCTs.74,87 Thanks to their cooperation, we were able to meta-analyze seven RCTs 
comprising a total of 3289 patients. 
All included studies either used nCPAP alone or nCPAP combined with surfactant 
administration via a thin catheter to avoid eMV. The meta-analysis showed that 
applying these strategies in preterm infants <30 weeks’ GA reduced the overall 
incidence of death or BPD from 42.4% to 39.6% (p=0.01, number needed to treat=35), 
without increasing the incidence of IVH.138 
The relatively small benefit of the “non-invasive approach” on the outcome death or 
BPD and the high percentage of preterm infants who eventually required intubation 
and eMV in the nCPAP groups (31-83% in the included RCTs) suggested that further 
studies are needed to improve the efficacy of non-invasive respiratory support. 
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2.2 Influence of nose and mouth leaks on peripheral oxygen 
saturation during continuous positive airway pressure in neonates 
Fischer HS, Roehr CC, Proquitté H, Schmalisch G. Influence of nose and mouth leaks 
on peripheral oxygen saturation during continuous positive airway pressure in 
neonates. World J Pediatr. 2013;9(4):318-322
The presence of leaks at the nasal interface or through the open mouth may have been 
one reason why nCPAP was less effective to avoid eMV in neonatal RCTs. In preterm 
infants with RDS, increasing levels of nCPAP (0, 2, 4, 6, and 8 cm H2O) were shown 
to result in higher tidal volumes, higher end-expiratory lung volumes and better 
thoracoabdominal synchronization.26 By contrast, nCPAP failure is often the 
consequence of a gradual clinical deterioration, which is heralded by increased CPAP- 
and oxygen requirements.139 Hypothetically, the presence of leaks could have a role 
in this process, as they impair pressure transmission to the airways116 and may 
therefore allow derecruitment of the lungs. To our knowledge, however, the impact of 
leaks on oxygenation and breathing pattern has never been investigated during 
neonatal CPAP. 
To assess the influence of leaks on oxygenation and RR in the clinical setting, we 
analyzed monitoring data from a previous randomized crossover trial of 32 newborns 
on nasopharyngeal CPAP.114 In this trial, peripheral oxygen saturation (SpO2) and RR 
measurements were taken with and without occlusion of the contralateral nostril, and 
were recorded in one-minute intervals over a 10-minute period during each condition. 
Mouth position was documented as “open” or “closed.” 
The study results showed no significant impact of nostril occlusion or mouth opening 
on SpO2. However, in a subgroup analysis of 17 infants with a SpO2 ≤93% during open 
nostril, active nostril occlusion resulted in a higher SpO2 [median(range) 91(80-96)% 
versus 89.5(78.5-93)%, p=0.036]. In the whole study group, RR was slightly lower 
during nostril occlusion [median(range) 48(32-85) min-1 versus 50.5(26-82) min-1, 
p=0.027].140 
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2.3 Exploring the prevalence, clinical application and side effects 
of nasal high-frequency oscillatory ventilation in neonatal intensive 
care units 
Fischer HS, Bohlin K, Bührer C, Schmalisch G, Cremer M, Reiss I, Czernik C. Nasal 
high-frequency oscillation ventilation in neonates: a survey in five European countries. 
Eur J Pediatr. 2015;174(4):465-471 
Hypercapnic respiratory failure is another reason why neonates may fail nCPAP 
therapy. This may occur due to poor respiratory drive or due to respiratory fatigue of 
the infant. NHFOV is a promising mode of non-invasive ventilation that combines the 
application of a continuous distending pressure with high-frequency oscillations to 
facilitate CO2 exhalation.17,18 To date, however, there is little evidence to support its 
efficiency and safety. 
To obtain information about the current clinical use and experience with nHFOV in 
neonates, we conducted a survey in five European countries (Austria, Switzerland, 
Germany, the Netherlands and Sweden). Clinical directors of NICUs who provide the 
highest level of care in their country were requested to provide data about their use of 
nHFOV. The 26-item questionnaire inquired about indications for nHFOV, equipment 
used, ventilator settings and side effects. 
Altogether, 172/186 (92%) of all contacted neonatologists took part in the survey, and 
30/172 (17%) of the participants affirmed the use of nHFOV. NICUs who used nHFOV 
differed substantially with regard to their nHFOV equipment, indications and settings. 
Interestingly, thick, almost solid secretions in 7/30 (23%) and upper airway obstruction 
due to secretions in 8/30 (27%) were reported as specific nHFOV side effects.141 
These observations suggested that nHFOV reduces air humidity in the upper airways, 
and may lead to the desiccation of secretions. The particular factors that caused this 
problem, however, were not known and required further research. 
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2.4 Influence of mouth opening on oropharyngeal humidification 
and temperature during neonatal continuous positive airway 
pressure 
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. Influence of mouth 
opening on oropharyngeal humidification and temperature in a bench model of 
neonatal continuous positive airway pressure. Med Eng Phys. 2017;40:87-94 
This bench model was designed to investigate factors that could negatively impact 
oropharyngeal humidity and temperature during non-invasive respiratory support of 
neonates. Because the unilateral leak flow through an open mouth was hypothesized 
to be one cause of upper airway desiccation, we placed importance on the simulation 
of open and closed mouth conditions. 
As shown in Fig. 1, an active lung model with adjustable RR was used to simulate 
infant breathing, and a modified rubber ball served as a model oropharynx. An 
interposed pass-over humidifier simulated the exhalation of heated and humidified air 
to the oropharynx. Oropharyngeal temperature and humidity were measured by a 
digital thermo-hygro sensor. An occludable opening in the model oropharynx allowed 
the simulation of mouth leaks. 
In the first set of measurements, the model was tested during unsupported breathing. 
It was shown that near-physiological gas conditions could be obtained in the model 
oropharynx and mouth opening had no significant effect. In the second set of 
measurements, the influence of mouth opening was investigated during nCPAP using 
three different scenarios: 1) no conditioning in the CPAP circuit, 2) heating only, and 
3) heated humidification. In all scenarios, mouth opening significantly reduced the
mean absolute humidity (AH) in the model oropharynx (p<0.001, respectively), which 
fell to an AH of 3.0 ±0.3 g m−3 without conditioning. During heated humidification, 
however, temperature and AH remained within clinically acceptable limits, regardless 
of whether the mouth was closed (AH 42.6 ±0.9 g m−3 with an occluded model mouth 
versus 35.7 ±1.9 g m−3 with an open mouth, p < 0.001).142
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Fig. 1 Experimental set-up used to investigate the influence of mouth opening on temperature 
and humidity in the model oropharynx. The model mouth was occluded with a cone-shaped 
silicone stopper as needed. Binasal prongs and the CPAP circuit were used in the second 
series of experiments. (Fischer et al., Med Eng Phys 2017; open access article under the CC 
BY-NC-ND license)142 
55
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. 
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.12.00556
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. 
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.12.00557
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. 
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.12.00558
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. 
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.12.00559
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. 
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.12.00560
Fischer HS, Ullrich TL, Bührer C, Czernik C
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.1, Schmalisch G. 
2.00561
C, S
.12.Fischer HS, Ullrich TL, Bührer C, Czernik 




6.1Fischer HS, Ullrich TL, Bührer C, Czerni
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.201, Schmalisch G. 
2.00563
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. 
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.12.005
64
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. 
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.12.005
65
Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G. 
Med Eng Phys. 2017;40:87-94 
https://doi.org/10.1016/j.medengphy.2016.12.005
66
2.5 Impact of nasal high-frequency oscillatory ventilation on 
oropharyngeal humidification and temperature 
Ullrich TL, Czernik C, Bührer C, Schmalisch G, Fischer HS. Nasal high-frequency 
oscillatory ventilation impairs heated humidification: a neonatal bench study. Pediatr 
Pulmonol. 2017;52(11):1455-1460 
The nHFOV survey indicated that upper airway obstruction due to highly viscous 
secretions is an adverse effect that occurred more frequently during nHFOV than 
during nCPAP (publication 2.3).141 Hypothetically, this may be due to a direct impact 
of nHFOV on oropharyngeal gas conditioning. We therefore investigated the effects of 
the nHFOV pressure oscillations on oropharyngeal T and AH, using the bench model 
described in publication 2.4 (Fig 1).142  
To differentiate the influence of different ventilatory settings, oropharyngeal 
temperature and humidity were measured at various nHFOV frequencies (7, 10, 13 
Hz), amplitudes (10, 20, 30 cm H2O), and inspiratory-to-expiratory ratios (I:E ratios) 
(25:75, 33:66, 50:50), and also during nCPAP. All experiments were conducted with 
an open model mouth. 
The use of nHFOV led to a lower temperature and AH in the model oropharynx in 
comparison with nCPAP (p<0.001, respectively). During nHFOV, decreasing 
frequency and increasing amplitude both impacted negatively on temperature and AH 
(p<0.001, respectively). Mean temperature and AH decreased from a maximum during 
nCPAP (T 34.8±0.6°C, AH 39.3±1.3 g∙m-3) to a minimum when nHFOV with a 
frequency of 7 Hz and an amplitude of 30 cm H2O was used (T 32.4 ± 0.3°C, AH 34.7 
± 0.5 g·m−3). Increasing the I:E ratio also resulted in a reduction of oropharyngeal 
temperature and AH (p = 0.03).143 
In summary, the bench data showed that nHFOV negatively impacted gas conditioning 
in the model oropharynx. In particular, intensified nHFOV settings with low frequencies, 
high amplitudes, and high I:E ratios may be associated with an increased risk of 
adverse effects due to upper airway desiccation in the clinical setting. 
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The present habilitation thesis relied on different methodologies to investigate the 
efficacy and safety of non-invasive respiratory support in neonates. Specifically, it 
included a meta-analysis, a clinical study, a survey and two in vitro studies using a 
newly-devised mechanical bench model. 
The meta-analysis explored the efficacy and safety of approaches aimed at avoiding 
eMV in the treatment of very premature infants with respiratory distress. It was shown 
that the use of non-invasive respiratory support strategies to avoid eMV reduced the 
incidence of death or BPD without increasing the risk of IVH.138 At the time, this was 
the largest meta-analysis investigating non-invasive respiratory support as an 
alternative to earlier intubation and surfactant, and the first to also include RCTs of 
surfactant administration via a thin catheter during nCPAP.73,74 Particular strengths of 
this meta-analysis were the strict adherence to Cochrane methodology in a 
predetermined study protocol,137 and the use of previously unpublished stratified data 
for infants <30 weeks’ GA. The latter allowed us to target those infants at the highest 
risk of BPD and IVH. The main limitation of our study was the restricted focus on only 
two outcomes (BPD and IVH). In spite of this, the meta-analysis supported the view 
that avoiding eMV by using nCPAP is beneficial and safe in preterm infants <30 weeks’ 
GA, and represents a viable alternative to early intubation and surfactant therapy. 
Since the completion of our meta-analysis, a considerable number of new RCTs and 
meta-analyses have been published that investigated specific strategies of non-
invasive respiratory support in very preterm infants. A meta-analysis of four RCTs by 
Schmölzer et al., published immediately prior to ours, evaluated the effect of nCPAP 
compared with intubation in preterm infants born at <32 weeks' GA. They reported a 
similar reduction in death or BPD at 36 weeks’ corrected GA, with a number needed to 
treat of 25, and found no differences in pneumothorax, severe IVH, and other adverse 
outcomes of prematurity.144 Similarly, an updated Cochrane review found that 
prophylactic nCPAP after birth in comparison with eMV reduced both the need for 
surfactant and the incidence of death or BPD in preterm infants born at <32 weeks' 
GA.145 Isayama et al. meta-analyzed RCTs that compared early INSURE with NCPAP 
in preterm infants of up to 35 weeks’ corrected GA and detected no difference in seven 
main outcomes, including BPD.146 More recently, surfactant application during nCPAP 
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has attracted particular attention, as these techniques appear to combine the benefits 
of surfactant with the benefits of a CPAP-only approach.147 The idea of surfactant 
administration by using a thin catheter during spontaneous breathing was first 
described by Verder et al. in 1992.148 Interestingly, this method of “less invasive 
surfactant administration” (LISA) was only developed further by Kribs et al. after the 
year 2000.71 It has since been adopted by many European NICUs,149,150 and was 
tested in a number of RCTs.73,74,89,151 Notably, the NINSAPP multi-center RCT 
compared LISA versus conventional surfactant application during eMV in extremely 
preterm infants of <27 weeks’ GA. Although LISA did not increase survival without 
BPD, LISA was associated with increased survival without major complications.89 Apart 
from LISA, other methods of less invasive surfactant delivery are emerging.147,152 Most 
importantly, Dargaville et al. devised a technique of surfactant application via 
orotracheal catheterization using a semi-rigid, narrow-bore vascular catheter. This 
method was termed “minimally invasive surfactant therapy” (MIST) and does not 
require the use of a Magill forceps.72 To date, it has only been tested in cohort studies 
and a pilot RCT,153-155 but in 2018, the first multi-center data of the “OPTIMIST-A” trial 
is awaited, which aims to assess the impact of MIST on survival without BPD in preterm 
infants of 25-28 weeks’ GA.156 For now, several conventional meta-analyses and a 
Bayesian random-effects network meta-analysis indicate that nCPAP in combination 
with LISA or MIST is currently the most efficient strategy of non-invasive respiratory 
support to reduce the combined outcome of death or BPD in preterm infants.157-160  
With regard to IVH, our meta-analysis confirmed that non-invasive respiratory support 
is a safe approach in the primary treatment of preterm infants with RDS. It implies that 
concerns about hypercapnia with consequential IVH during nCPAP treatment are 
unsubstantiated if appropriate thresholds for “rescue” intubation and surfactant are set. 
This finding is in accordance with recent results of a multi-center RCT and a meta-
analysis in mechanically-ventilated preterm infants, which showed that the incidence 
of severe IVH did not increase if higher than normal pCO₂ values of up to 65 mmHg 
were accepted on days one to three.161,162 
While a lot of research activities were dedicated to the investigation of surfactant and 
specific non-invasive respiratory support strategies in very preterm infants, there is 
only limited knowledge about the significance of leaks during neonatal CPAP. In a 
clinical crossover study of experimental nostril occlusion in 32 neonates on 
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nasopharyngeal CPAP, we assessed the influence of nose leaks and spontaneous 
mouth opening on SpO2 and RR. Nostril occlusion resulted in a marginal reduction of 
RR, but had no effect on SpO2. Only in a subgroup of 17 infants with a SpO2 ≤93% 
during open nostril, median SpO2 increased from 89.5 to 91% during nostril occlusion. 
No effects of mouth opening could be shown.140 To our knowledge, this was the first 
clinical study that investigated the impact of leaks on SpO2 and RR during neonatal 
CPAP. It is reasonable to assume that the positive effect of nostril occlusion on SpO2 
was due to improved CPAP transmission,116 as CPAP is known to stabilize functional 
residual capacity and oxygenation.23,29 If leak reduction improves oxygenation during 
neonatal CPAP therapy, this finding might be clinically relevant, as intermittent 
hypoxemic episodes were associated with severe retinopathy of prematurity in infants 
of <28 weeks’ gestation.163 The present study results, however, need to be interpreted 
with caution. First, the effects on SpO2 were only evident in a subgroup analysis, and 
the effect size was small. Second, the study only assessed short-term effects on two 
monitoring parameters, whereas the long-term outcomes of leak reduction remain 
unknown. Third, too few study patients opened and closed their mouths during the 
measurement period to assess the true impact of mouth leaks. 
From a clinical point of view, nose leaks are nowadays easily minimized by the use of 
a closely-fitting binasal prong interface, whereas mouth leaks remain a significant 
problem. To date, it is unknown whether deliberate mouth occlusion would result in 
better long-term outcomes, and our study did not address this question. Interestingly, 
chin straps and pacifiers have recently been recommended to reduce mouth leaks and 
maintain airway pressure during nCPAP.84 The efficacy and safety of these measures, 
however, remains to be proven. A recent crossover trial by Ahmadpour-Kacho 
investigated the introduction of a pacifier to elicit non-nutritive sucking in 25 preterm 
infants treated with nCPAP. The intervention resulted in a small but statistically 
significant increase of SpO2 from 96.3 to 98.4%.164 Overall, the limited data available 
suggests that measures to reduce leaks during neonatal CPAP may have small 
beneficial effects and warrant further clinical studies. 
The use of nHFOV is another approach to enhance the beneficial effects of nCPAP. 
Due to the paucity of clinical data about nHFOV, we decided to conduct a survey in the 
tertiary NICUs of five European countries. Surprisingly, nHFOV was already being 
used by 30/172 (17%) of the responders. The substantial differences in nHFOV 
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equipment, indications and settings reported by the survey participants underlined the 
urgent need for clinical trials about nHFOV. Notably, for the first time, “thick secretions” 
and “upper airway obstruction due to secretions” were reported as specific nHFOV side 
effects that occurred more frequently during nHFOV than during nCPAP.141 This was 
the very first survey dedicated to nHFOV, and the first study that inquired into its side 
effects. The results can be considered representative due to the 92% response rate 
and the detailed responses of all nHFOV users. The main limitation was the obvious 
fact that the survey data was merely based on individual experiences and preferences. 
As these may have been subjective or biased, the efficacy of nHFOV still needs to be 
proven. Another limitation was the restricted focus on European countries. 
In the meantime, Mukerji et al. have conducted a survey of non-invasive respiratory 
support practices in Canada. With a response rate of 93%, a reported nHFOV use of 
5/28 (18%) in tertiary NICUs and a wide variation of clinical practices, their results were 
similar to the European survey.165 A number of clinical reports, a crossover trial and 
two pilot RCTs have since enhanced our knowledge about nHFOV’s clinical efficacy: 
Aktas et al. presented a small case series of nHFOV application via a new binasal 
cannula interface in extremely low birthweight infants. They successfully used nHFOV 
to avoid reintubation in three patients.166 In the abstract of a cohort study published in 
Chinese language by Wang et al., they confirmed previous reports that nHFOV in very 
low birthweight infants was associated with a reduction of apneas, oxygen 
desaturations and pCO2.167 For the first time, De Luca et al. tested nHFOV in four older 
infants/toddlers of about one year old. They documented an effective pressure 
transmission by a face mask, but also observed a considerable dampening effect of 
the pressure oscillations between the ventilator and the mask.168 Mukerji et al. reported 
a pilot RCT of nHFOV versus nBiPAP in 39 infants with a birthweight of <1250 g who 
failed nCPAP therapy. They could not show statistically significant effects, but there 
was a trend towards less treatment failure in the nHFOV group (38% versus 65%, 
p=0.09).169 In a clinical crossover trial, Klotz et al. compared nHFOV with nCPAP in 26 
preterm infants <32 weeks’ GA following LISA or extubation. They found that the pCO2 
after four hours of nHFOV compared with four hours of nCPAP was not different.170 In 
a pilot RCT of nHFOV versus nCPAP in preterm infants with moderate to severe RDS, 
Zhu et al. showed a reduced need for eMV in the nHFOV group (24% versus 56%, 
p<0.01).171  
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In spite of the aforementioned reports, the overall data about the efficacy of nHFOV is 
still limited. The available evidence from recent trials suggests some clinical benefits 
for nHFOV, but also indicates that pilot studies from single centers will be insufficient 
for examining long-term outcomes. Future RCTs should therefore employ a multi-
center approach, focusing on those infants with a high risk of BPD and other 
complications of prematurity. In particular, it might be promising to conduct a multi-
center RCT to investigate nHFOV in the primary treatment of more severe RDS in 
preterm infants of 24-28 weeks’ GA.172 
With regard to adverse effects, only the cohort study by Wang et al. reported nasal 
septum injury in 4/36 (11%) of all nHFOV cases,167 but this could have happened 
likewise during nCPAP. Overall, it is encouraging that side effects seemed to be 
extremely rare in all clinical reports of nHFOV. The aforementioned studies, however, 
were neither designed nor powered to detect specific adverse events. Importantly, 
further research was needed to clarify the apparent nHFOV-related side effects of 
upper airway obstruction due to highly viscous secretions reported in the European 
survey. As previously mentioned, similar symptoms of crusting secretions and tube 
blockage were observed during nasopharyngeal CPAP prior to the era of heated 
humidification.130 We therefore hypothesized that nHFOV negatively impacts heated 
humidification and thus allows desiccation of the upper airways. Because temperature 
and humidity measurements in the upper airways would be extremely intricate in 
neonates, we decided to design a neonatal bench model suitable for simulating 
oropharyngeal gas conditions during non-invasive respiratory support. 
The neonatal bench model was first devised to investigate the impact of mouth opening 
on oropharyngeal temperature and AH during nCPAP. Initial experiments during 
unsupported breathing confirmed that the model was suitable for simulating stable and 
near-physiological temperature and humidity in the model oropharynx. During nCPAP, 
the mouth leak had a considerable negative impact on temperature and AH during 
three different scenarios of gas conditioning. With heating only or without gas 
conditioning, the AH reductions were extreme and resulted in AH values of <4.5 g·m-3, 
respectively. Even during heated humidification, mouth opening considerably impaired 
oropharyngeal gas conditions, with a decrease in AH from 42.6 g·m−3 to 35.7 g·m−3.142 
To our knowledge, this was the first study to specifically investigate the impact of mouth 
leaks on upper airway temperature and AH during neonatal CPAP. The new bench 
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model combined several well-established features, such as a thermo-stable incubator 
environment,3,173 a miniaturized thermo-hygro sensor133 and the intentional simulation 
of a mouth leak.41 Furthermore, an extra heated humidifier was interposed between 
the active model lung and the oropharynx to simulate the recurrent expiration of heated 
and humidified air (Fig. 1). In spite of these efforts to create realistic gas conditions in 
the model oropharynx, the study results need to be interpreted cautiously. It is obvious 
that the mechanical bench model greatly simplified the pharyngeal anatomy, and was 
not designed to simulate the complex physiology of heat and moisture exchange in the 
upper airways.125,126,174 Moreover, the accuracy of the capacitive humidity sensor may 
have been limited during high humidity levels.175 On the other hand, the bench study 
yielded reproducible results that were entirely plausible. Mouth leaks are recognized 
contributors to oropharyngeal gas conditions during non-invasive respiratory 
support,121 and the findings of reduced oropharyngeal temperature and AH during 
mouth leaks are consistent with clinical studies in adults.119,129 
In the future, the present bench model could assist in shedding light on the factors that 
influence oropharyngeal gas conditions during non-invasive respiratory support in 
neonates. In particular, the model would be suited for investigating the impact of mouth 
leaks during different non-invasive respiratory support modes and to assess the impact 
of different ventilatory settings. It could also be applied to compare different equipment, 
such as various ventilatory devices, interfaces or heated humidifiers. Recently, we 
used the model to conduct a bench study of neonatal HFNC. During occluded mouth, 
oropharyngeal temperature and AH increased with increasing flow. In the presence of 
an open mouth, however, temperature and AH plateaued if flows of >6 L∙min-1 were 
applied.176 To answer the original question of whether nHFOV influences heated 
humidification, another bench study was performed. 
The bench study of nHFOV aimed to investigate the impact of the nasal high-frequency 
oscillations on oropharyngeal temperature and AH. For this purpose, measurements 
were conducted during nHFOV using different ventilatory parameters, and during 
nCPAP. As the previous study during nCPAP had shown that the open mouth condition 
represents the greatest challenge for heated humidification, all measurements were 
taken during open mouth. In comparison with nCPAP, nHFOV impaired the 
oropharyngeal gas conditions, with a resultant decrease in AH from a maximum of 
39.3 g∙m-3 to a minimum of 34.7 g∙m-3. Specifically, lower nHFOV frequencies, higher 
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amplitudes, and higher I:E ratios reduced temperature and AH in the model 
oropharynx.143 As these are results of a bench study, they should ideally be confirmed 
in a clinical trial. In particular, it is difficult to say which decreases of temperature and 
AH would be clinically relevant to avoid side effects during nHFOV. In spite of this, the 
present study clearly showed that nHFOV negatively impacted oropharyngeal gas 
conditions, and thus indicated that previously reported adverse events of highly 
viscous secretions and consecutive upper airway obstruction can be related directly 
with the use of nHFOV. 
Interestingly, the decreased efficiency of heated humidification was associated with 
ventilatory settings of nHFOV that are known to enhance nHFOV tidal volume and CO2 
elimination.54,177 Although the exact mechanisms of heat and moisture exchange 
during nHFOV still need to be elucidated, these findings are of immediate clinical 
relevance. Clinicians should be aware that intensifying ventilatory settings of nHFOV 
puts their patients at increased risk of upper airway desiccation and potentially 
dangerous airway obstruction. Hypothetically, even partial airway obstruction could 
increase airway resistance and may represent an under-recognized reason for nHFOV 
failure. Preemptive measures to avoid these problems are needed but have never 
been explored. According to our previous study about the impact of mouth leaks during 
nCPAP, leak reduction by a chin strap or a pacifier could theoretically be an option for 
improving oropharyngeal gas conditioning.142 However, a recent bench study by Klotz 
et al. showed that moderate leakage is necessary to achieve the most effective CO2 
elimination during nHFOV.53 Future bench studies and clinical trials should therefore 




Non-invasive respiratory support is nowadays a mainstay of treatment in neonates with 
respiratory failure. Established treatment options such as nCPAP have been refined 
over the years. Innovative strategies of non-invasive respiratory support are evolving, 
but quite often there is a paucity of evidence to support their use. The present 
habilitation thesis applied different methodologies to address specific research 
questions relating to the efficacy and safety of these new approaches. 
In a meta-analysis of RCTs, we showed that non-invasive respiratory support 
strategies to avoid eMV reduced the incidence of death or BPD without increasing IVH 
in preterm infants of <30 weeks’ GA. In a clinical crossover study, we investigated the 
impact of experimental leak reduction in 32 neonates on nasopharyngeal CPAP but 
detected only minor beneficial effects on oxygenation. In an international survey, we 
gained insights about the current clinical use of nHFOV in tertiary NICUs. We 
encountered a great variety of clinical practices and identified upper airway obstruction 
due to highly viscous secretions as a specific adverse effect of nHFOV. In a dedicated 
neonatal bench model, we further investigated the determinants of oropharyngeal gas 
conditions during non-invasive respiratory support. A bench study during nCPAP 
showed that mouth opening reduced oropharyngeal temperature and AH, even during 
heated humidification. A second bench study showed that nHFOV additionally 
impaired oropharyngeal gas conditions and that the magnitude of this effect depended 
on the ventilatory settings of nHFOV. 
From a clinical point of view, the meta-analysis results approved the use of non-
invasive respiratory support in the primary treatment of preterm infants with RDS, but 
the large number needed to treat to prevent one case of death or BPD clarified that a 
comprehensive approach of different measures is required to effectively reduce BPD 
in very preterm infants. The nHFOV survey provided information about the clinical 
experiences with this novel mode, but as evidence about its efficacy and safety is still 
limited, its clinical application should be confined to individual patients and RCTs. 
Importantly, the survey and the bench studies suggest that nHFOV patients are at risk 
of upper airway obstruction due to thick secretions, especially when intensified 
ventilatory settings (low nHFOV frequency, high amplitude, high I:E ratio) are applied 
in the presence of mouth leaks. 
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According to the results of this thesis, the following four areas will require additional 
research: 
1) Innovative ways of surfactant administration should be advanced as a means to
avoid eMV in preterm infants, as early surfactant administration during nCPAP 
currently appears to be the most effective respiratory intervention to avoid BPD. 
2) Adjunctive measures to improve pressure transmission during nCPAP, such as chin
straps or pacifiers, should be investigated in clinical trials. 
3) Bench studies are warranted to optimize heated humidification during nHFOV.
4) Appropriately powered multi-center RCTs will be needed to investigate the efficacy
and safety of nHFOV, and should focus on preterm infants at high risk of BPD. 
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